

Mogrify
Generated by Meeveem AI
"Developing in vivo cell reprogramming therapies for degenerative diseases"
About Mogrify
Mogrify is a Cambridge regenerative medicine company developing in vivo cell-reprogramming therapies for degenerative diseases. Its MOGRIFY and epiMOGRIFY platforms use computational analysis of gene-expression and epigenetic data to identify factors that can change or maintain a cell’s identity. The aim is to generate functional cells where disease or injury has caused their loss.
The company applies this approach across ophthalmology, otology, diabetes and other areas of unmet clinical need. Its business combines its own therapy development with co-development partnerships and other applications of the platforms. Mogrify’s history dates its establishment to 2016, following earlier academic research into direct cellular conversion.

Research and employee support
Mogrify’s careers page presents work developing therapies alongside colleagues and external collaborators. Its published package includes a contributory pension, health and dental insurance with family cover available, income protection and life assurance. It also describes a share option scheme after 12 months of continuous employment and 25 days of annual leave, increasing to 30.

15
Team Members
2016
Founded
Biotechnology
Sector
Hybrid
Work Environment
Open Positions
Join our team! Explore current opportunities at Mogrify.
No open positions at the moment.
Check back soon for new opportunities!